NCT06803771 Surveillance of Pancreatic Health After Diabetes Diagnosis
| NCT ID | NCT06803771 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Southampton NHS Foundation Trust |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2025-05-21 |
| Primary Completion | 2028-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15,000 participants in total. It began in 2025-05-21 with a primary completion date of 2028-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.
Eligibility Criteria
Inclusion Criteria: * 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth) * Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and/or confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance) * Willing to provide up to 30 mL of blood for each study visit * Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated) * Understands the study process and is willing to take part in the study and sign the informed consent form Exclusion Criteria: * Prior type I or type II DM diagnosis \> 6 months * A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis * Under investigation for pancreatic cancer / pancreatic cyst * Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months * Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years * Current chronic or acute oral or systemic steroid use within 3 months of initial HbA1c or diabetes diagnosis (estimate rather than accurate) * Blood transfusion within 1 month * Solid organ transplant recipient * Currently pregnant * Needing dialysis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06803771 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 84 Years, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06803771 currently recruiting?
Yes, NCT06803771 is actively recruiting participants. Contact the research team at safed@soton.ac.uk for enrollment information.
Where is the NCT06803771 trial being conducted?
This trial is being conducted at Sandbach, United Kingdom, Maidstone, United Kingdom, Uttoxeter, United Kingdom, Leicester, United Kingdom and 11 additional locations.
Who is sponsoring the NCT06803771 clinical trial?
NCT06803771 is sponsored by University Hospital Southampton NHS Foundation Trust. The trial plans to enroll 15,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.